← All tickers

Is COGT Worth Buying in 2026?

Cogent Biosciences, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-23

Here’s whether Cogent Biosciences, Inc. Common Stock (COGT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+2.68% over 10 days); RSI 43 — healthy momentum range; strong 1-year return of +212.1%; 3-month momentum positive (+12.4%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 16.0% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

COGT is holding above its long-term 200-day MA ($36.48) but has slipped below the 50-day MA ($38.34), pointing to short-term weakness in an otherwise intact trend. An RSI of 43.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +212.1% compares to +20.5% for SPY (beat the market by 191.6%).

$10,000 invested 1 year ago → $31,206 today
vs. S&P 500 (SPY) — same period beat market by 191.6%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($36.48)
✗Above 50-day MA ($38.34)
✓RSI(14) neutral zone (30–70) — currently 43.3
✓Positive return (+212.1%)
!Within 10% of period high (−16.0%)
Period Range $36.73
$11.60 $43.73
RSI (14) 43.3
0 · OversoldOverbought · 100

Key Metrics

Price$36.73
Period Return+212.1%
Period High$43.73
Period Low$11.60
Drawdown−16.0%
MA-50$38.34
MA-200$36.48
RSI (14)43.3
Avg Volume (30d)1.9M
vs. SPYbeat by 191.6%
Return Rank#51 of 999

Trade COGT

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers